Results 51 to 60 of about 27,566 (165)

Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case report

Journal of Medical Case Reports, 2011
Introduction The monoclonal anti-vascular endothelial growth factor antibody bevacizumab is increasingly used in the treatment of several malignant tumors. The usual side effects of this drug are hypertension and proteinuria. Paclitaxel is widely used in
Koulu Leena, Kivisaari Atte, Paija Outi, Vihinen Pia, Aho Heikki   +4 more
doaj   +1 more source

Associação entre lúpus eritematoso e tabagismo Association between lupus erythematosus and smoking

Anais Brasileiros de Dermatologia, 2008
FUNDAMENTOS: O lúpus eritematoso é doença crônica, auto-imune, que reúne manifestações exclusivamente cutâneas ou multissistêmicas, caracterizada pela produção de auto-anticorpos contra vários constituintes celulares.
Júnia Maria Fernandes Araújo, Ana Rosa Magaldi Ribeiro de Oliveira, Sâmya Diégues Cedrim, Olímpia Castelo Tristão, Aloísio Gamonal   +4 more
doaj   +1 more source

Pregnancy and lactation during anifrolumab treatment in systemic lupus erythematosus

Dermatology Reports
Dear Editor, Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease that predominantly affects women of childbearing age. Cutaneous involvement represents one of the most common clinical manifestations of SLE and may occur in ...
Maria Bernardette Cilona, Giovanni Paolino, Luca Moroni, Giuseppe Alvise Ramirez, Federica Pasi, Eleonora Sabetta, Antonella Poloniato, Federica Barzaghi, Maria Teresa Castiglioni, Valentina Canti   +9 more
doaj   +1 more source

Cutaneous Lupus Erythematosus

Dalhousie Medical Journal, 2013
Lupus erythematosus (LE) is a heterogeneous group of chronic autoimmune inflammatory diseases, ranging from solely cutaneous symptoms to systemic disease with extensive visceral involvement. 1 Lupus was first named in the Middle Ages, but evidence suggests that Hippocrates described it long before that time.
openaire   +2 more sources

Indexes of skin activity and damage in patients with systemic lupus erythematosus – CLASI and R-CLASI

Научно-практическая ревматология
Introduction. Cutaneous Lupus Disease Area and Severity Index (CLASI) and its modified version, the Revised Cutaneous Lupus Erythematosus Disease Areas and Severity Index (R-CLASI) are tools for quantifying skin and mucosal lesions in patients with both ...
А. А. Shumilova, F. A. Cheldieva, К. S. Nurbaeva, Е. I. Travkiva, Т. М. Reshetnyak   +4 more
doaj   +1 more source

Rapid clearance of cutaneous lesions with anifrolumab in SLE (systemic lupus erythematosus) and DLE (discoid lupus erythematosus)

JEADV Clinical Practice
Background Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs, including the skin. Activation of the Type I interferon pathway is a key pathophysiological factor in SLE. Discoid lupus erythematosus (DLE) is a chronic
E. Parriel, C. Bulai‐Livideanu, M. Severino‐Freire, A. Delpuech, S. Faguer, J. Belliere, A. Huart, C. Paul   +7 more
doaj   +1 more source

Successful use of anifrolumab in refractory cutaneous lupus erythematosus with systemic lupus erythematosus: A case report

SAGE Open Medical Case Reports
A 61-year-old female with systemic lupus erythematosus presented with refractory discoid lupus. Despite treatment with numerous immunosuppressive therapies, including prednisone, hydroxychloroquine and mycophenolate mofetil, her cutaneous lupus remained ...
Abdullah Ramadhan, Anita Troung, Elaine Yacyshyn, Robert Gniadecki   +3 more
doaj   +1 more source

Current Insights Into The Management Of Discoid Lupus Erythematosus

Clinical, Cosmetic and Investigational Dermatology, 2019
Jaime Company-Quiroga,* Sergio Alique-García,* Alberto Romero-MatéDermatology Department, Fuenlabrada Univesity Hospital, Madrid, Spain*These authors contributed equally to this workCorrespondence: Jaime Company-QuirogaDermatology ...
Company-Quiroga J, Alique-García S, Romero-Maté A   +2 more
doaj  

Lupus erythematosus tumidus: clinical perspectives

Clinical, Cosmetic and Investigational Dermatology, 2019
Nikolaos Patsinakidis,1,2 Ocko Kautz,1 Bernhard F Gibbs,2 Ulrike Raap1,2 1University Clinic of Dermatology and Allergology, University of Oldenburg, Klinikum Oldenburg Aör, Oldenburg, Germany; 2Division of Experimental Allergy and Immunodermatology,
Patsinakidis N, Kautz O, Gibbs BF, Raap U   +3 more
doaj  

Significant improvement of refractory cutaneous lesions of lupus erythematosus with the use of anifrolumab: a report of two cases

Revista da Sociedade Portuguesa de Dermatologia e Venereologia
Anifrolumab, a monoclonal antibody targeting the interferon-1 receptor, is currently approved for the treatment of moderate- to-severe systemic lupus erythematosus, but emerging evidence highlights its potential efficacy in cases with predominant ...
Gilberto P. da Rosa, Isabel Antunes, Bárbara V. Granja, Patrícia Gomes, Rúben Costa, Filomena Azevedo, Alberto Mota   +6 more
doaj